Abstract
In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.
| Original language | English |
|---|---|
| Pages (from-to) | 283-292 |
| Number of pages | 10 |
| Journal | Anti-Cancer Agents in Medicinal Chemistry |
| Volume | 10 |
| Issue number | 4 |
| Publication status | Published - May 2010 |
Fingerprint
Keywords
- Anticancer drug
- Dithiocarbamate
- Gold compounds
- Metallodrug
- Nephrotoxicity
- Proteasome inhibitor
- Reactive oxygen species (ROS)
- Thioredoxin reductase (TrxR)
ASJC Scopus subject areas
- Cancer Research
- Molecular Medicine
- Pharmacology
Cite this
Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes. / Ronconi, Luca; Aldinucci, Donatella; Dou, Q. Ping; Fregona, Dolores.
In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 10, No. 4, 05.2010, p. 283-292.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes
AU - Ronconi, Luca
AU - Aldinucci, Donatella
AU - Dou, Q. Ping
AU - Fregona, Dolores
PY - 2010/5
Y1 - 2010/5
N2 - In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.
AB - In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.
KW - Anticancer drug
KW - Dithiocarbamate
KW - Gold compounds
KW - Metallodrug
KW - Nephrotoxicity
KW - Proteasome inhibitor
KW - Reactive oxygen species (ROS)
KW - Thioredoxin reductase (TrxR)
UR - http://www.scopus.com/inward/record.url?scp=77951660776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951660776&partnerID=8YFLogxK
M3 - Article
C2 - 20184554
AN - SCOPUS:77951660776
VL - 10
SP - 283
EP - 292
JO - Anti-Cancer Agents in Medicinal Chemistry
JF - Anti-Cancer Agents in Medicinal Chemistry
SN - 1871-5206
IS - 4
ER -